These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21933768)

  • 1. A case of exhaustion of implantable cardioverter defibrillator therapies due to inappropriate programming.
    Fragakis NK; Antoniadis AP; Geleris P
    Hellenic J Cardiol; 2011; 52(4):354-6. PubMed ID: 21933768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between age and inappropriate implantable cardioverter-defibrillator therapy in MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy).
    Biton Y; Huang DT; Goldenberg I; Rosero S; Moss AJ; Kutyifa V; McNitt S; Strasberg B; Zareba W; Barsheshet A
    Heart Rhythm; 2016 Apr; 13(4):888-93. PubMed ID: 26711799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD).
    Guerra F; Palmisano P; Dell'Era G; Ziacchi M; Ammendola E; Bonelli P; Patani F; Cupido C; Devecchi C; Accogli M; Occhetta E; Santangelo L; Biffi M; Boriani G; Capucci A;
    Heart Rhythm; 2016 Oct; 13(10):1987-92. PubMed ID: 27291511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programming implantable cardioverter-defibrillator therapy zones to high ranges to prevent delivery of inappropriate device therapies in patients with primary prevention: results from the RISSY-ICD (Reduction of Inappropriate ShockS bY InCreaseD zones) trial.
    Cay S; Canpolat U; Ucar F; Ozeke O; Ozcan F; Topaloglu S; Aras D
    Am J Cardiol; 2015 May; 115(9):1235-43. PubMed ID: 25765588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of third-generation implantable cardioverter defibrillators to abort shock therapy for nonsustained ventricular tachycardia due to shortcomings of the VF confirmation algorithm.
    Grimm W; Menz V; Hoffmann J; Maisch B
    Pacing Clin Electrophysiol; 1998 Apr; 21(4 Pt 1):722-7. PubMed ID: 9584303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study.
    Schwab JO; Bonnemeier H; Kleemann T; Brachmann J; Fischer S; Birkenhauer F; Eberhardt F
    Clin Res Cardiol; 2015 Dec; 104(12):1021-32. PubMed ID: 26002818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter defibrillator events in patients with asymptomatic nonsustained ventricular tachycardia: is device implantation justified?
    Russo AM; Nayak H; Verdino R; Springman J; Gerstenfeld E; Hsia H; Marchlinski FE
    Pacing Clin Electrophysiol; 2003 Dec; 26(12):2289-95. PubMed ID: 14675014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inadequate therapies with implantable cardioverter-defibrillators--incidence, etiology, predictive factors and preventive strategies].
    Weber M; Block M; Brunn J; Bänsch D; Böcker D; Hammel D; Gietzen F; Breithardt G
    Z Kardiol; 1996 Nov; 85(11):809-19. PubMed ID: 9064943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mean ventricular fibrillation cycle length: a potentially useful parameter for programming implantable cardioverter defibrillators.
    Li H; Easley A; Windle J; Samoil D; Barrington W
    Pacing Clin Electrophysiol; 1998 Sep; 21(9):1789-94. PubMed ID: 9744444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of idiopathic ventricular tachycardia with ventricular fibrillation successfully treated with cryoablations and implantable cardioverter defibrillator].
    Nitta T; Tanaka S; Imura H; Terada K; Ikeshita M; Shoji T
    Nihon Kyobu Geka Gakkai Zasshi; 1992 Aug; 40(8):1279-84. PubMed ID: 1402174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the fifth-generation implantable cardioverter defibrillator.
    Tanaka S
    Ann Thorac Cardiovasc Surg; 1998 Dec; 4(6):303-11. PubMed ID: 9914457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fully automatic, implantable cardioverter-defibrillator algorithm to prevent inappropriate detection of ventricular tachycardia or fibrillation due to T-wave oversensing in spontaneous rhythm.
    Cao J; Gillberg JM; Swerdlow CD
    Heart Rhythm; 2012 Apr; 9(4):522-30. PubMed ID: 22094074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator.
    Dorian P; Philippon F; Thibault B; Kimber S; Sterns L; Greene M; Newman D; Gelaznikas R; Barr A;
    Heart Rhythm; 2004 Nov; 1(5):540-7. PubMed ID: 15851216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients.
    Hayashi Y; Takagi M; Kakihara J; Sakamoto S; Doi A; Sugioka K; Hanatani A; Yoshiyama M
    Heart Vessels; 2017 Feb; 32(2):175-185. PubMed ID: 27259484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.